Prescient Therapeutics (ASX:PTX) has announced that its abstract for the results of a Phase 1b study in T-cell lymphomas has been accepted for poster presentation at the American Society of Hematology annual meeting in December.
The meeting is the largest and most comprehensive hematology conference in the world.
Prescient Therapeutics managing director and CEO, Steven Yatomi-Clarke, said, “It is a huge honour to have our abstract presented at the world’s most prestigious haematology conference. This is a validation of the quality and relevance of the clinical data we are generating in T-cell lymphomas, which is an area of unmet clinical need. It is also a testament to the hard work by the Prescient team and our clinical collaborators.
“Prescient looks forward to presenting this data at ASH and will release this data to the market concurrently.”
